Magazine Article | November 8, 2017

Pet Medicines: Smaller Market, Lower Costs, Greater Margins

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical

Making the move from a pharmaceutical firm to an animal health company might seem like taking a small step from one drug discovery organization to another. But that transition process for one executive was a bigger challenge than he expected, and now it has him looking at the drug discovery process in a new way.

After receiving his doctorate from Harvard Medical School, Richard Chin began his pharma career by serving as medical director at P&G Pharmaceuticals. That was followed by stints at Genentech, Elan Pharmaceuticals, Oxigene, and a few other firms working on drugs for arthritis, asthma, and eye diseases. But as an animal lover, Chin was always thinking about ways in which he could use his pharma experience to improve the lives of pets.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.